Concepedia

Publication | Open Access

Selection and early clinical evaluation of the brain‐penetrant 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor UE2343 (Xanamem™)

DOIFull Paper Access

52

Citations

31

References

2016

Year

Scott P. Webster, Andrew McBride, Margaret Binnie, Karen Sooy, Jonathan R. Seckl, Ruth Andrew, T. David Pallin, Hazel Hunt, Trevor R. Perrior, Vincent Ruffles,
British Journal of Pharmacology

Abstract

UE2343 is safe, well tolerated and reaches the brain at concentrations predicted to inhibit 11β-HSD1. UE2343 is therefore a suitable candidate to test the hypothesis that 11β-HSD1 inhibition in brain improves memory in patients with AD.

References

YearCitations

Page 1